Nothing more controversial than PGScme-utilities.com/mailshotcme/Material for Websites/OC... ·...
Transcript of Nothing more controversial than PGScme-utilities.com/mailshotcme/Material for Websites/OC... ·...
-
Nothing more controversial than PGS Norbert G le icher, MD M e d i c a l D i r e c t o r a n d C h i e f S c i e n t i s t , C e n t e r F o r H u m a n R e p ro d u c t i o n , N e w Yo r k , N Y P r e s i d e n t , F o u n d a t i o n F o r R e p ro d u c t i v e M e d i c i n e , N e w Yo r k , N Y G u e s t I n v e s t i g at o r, R o c ke fe l l e r U n i v e rs i t y, N e w Yo r k , N Y P r o fe s s o r ( A d j ) , D e p a r t m e n t O f O b s t e t r i c s & G y n e c o l o g y, V i e n n a U n i v e rs i t y S c h o o l O f M e d i c i n e , V i e n n a , A u s t r i a
Ovarian Club IX| September 15-16, 2017 | Barcelona, Spain
-
Conflict Statement Dr. Gleicher is listed as co-inventor on a number of pending patent applications claiming diagnostic and therapeutic benefits from determination of CGG repeat numbers and ovarian FMR1 genotypes and sub-genotypes.
Dr. Gleicher is co-inventor of awarded U.S. patents, claiming therapeutic benefits for supplementation of DHEA in women with diminished ovarian reserve, a topic discussed in this talk. Other patent applications in regards to DHEA and other fertility-related claims, with no relationship to this talk, are pending. Dr. Gleicher receives royalties from, and owns shares in Fertility Neutraceuticals, LLC, a distributor of a DHEA product.
Dr. Gleicher is co-inventor of three pending patent applications claiming potential therapeutic benefit for anti-Müllerian hormone (AMH) in infertile women. Dr. Gleicher owns shares in OvaNova Laboratories, LLC.
-
The PGS Hypothesis Aneuploidy is a major cause of IVF failure and
miscarriages after IVF
Elimination of aneuploid embryo before embryo transfer, therefore, will improve IVF outcomes and reduce miscarriages
-
History Polar body biopsy (Verlinsky et al 1990s)
PGS 1.0 (~2000-2008)
PGS 2.0 (2008-2017)
PGS 3.0/PGT-A (as of July 2017)
-
History cont. PBB, PGS 1.0 and PGS 2.0, all, reported results as
euploid/aneuploidy
Only PGS 3.0/PGT-A reports results as euploid/mosaic/aneuploid
-
“Implementation of the most recent PGS technologies has been shown to improve pregnancy rates per transfer in randomized controlled trials, meta-analysis and case-controlled prospective studies.”
Besser and Mounts 2017
-
The errors in IVF outcome assessments with reference embryo transfer
n=10
PGS
Blastocysts
Selection by OR
General population (n=100)
Assuming 8 live births, the live birth rate will be 80% with reference ET, but only 8% with reference cycle start (“intent to treat”)
-
Is there evidence that the PGS hypothesis does not work? 2 models Orvieto R, Reprod Biol Endocrinol 2016
Scriven PN, Reprod Biol Endocrinol 2017
-
Barad DH et al, Am J Obstet Gynecol 2017
-
The Value of PGS
-
Can a single TEB reliably reflect the whole TE?
-
P-values for observing no mosaicism, given different hypotheses r and a threshold of 0.05 (dotted line)
P-values for observed mosaicism, given different hypotheses r, and varying numbers of abnormal-aneuploidy cells in biopsy
Reprod Biol Endocrinol; In press
-
Effects of Pre-Implantation Chromosome Mosaicism on Embryo Development and Survival
-
Richard J. Paulson • Preimplantation genetic screening: What is the
clinical efficiency? • Fertil Steril 2017;108:228-230
• “We must be cognizant of the reality that this type of screening is inherently inefficient and that many normal embryos are discarded”
• “The proportion of normal embryos that are discarded...may be as high as 40%”
-
Greco and et al, N Engl J Med 2015;373:2089-90.
-
Bernabeu et al ESHRE 2016
Mosaic Euploid
Age (years) 31.0 30.6
Embryos (n) 54 382
Clinical pregnancies (%) 26.9% 40.2%
Clinical miscarriages (%) 7.1% 18.1%
Ongoing pregnancies (%)* 25.0% 32.9%
* All births normal
-
OBJECTIVE: To determine the pregnancy outcome potential of mosaic embryos, detected by means of preimplantation genetic screening (PGS) with the use of next-generation sequencing (NGS). DESIGN: Retrospective study. SETTING: Genetics laboratories. PATIENT(S): PGS cycles during which either mosaic or euploid embryos were replaced. INTERVENTION(S): Blastocysts were biopsied and processed with the use of NGS, followed by frozen embryo transfer. Trophectoderm (TE) biopsies were classified as mosaic if they had 20%-80% abnormal cells. MAIN OUTCOME MEASURE(S): Implantation, miscarriage rates, and ongoing implantation rates (OIRs) were compared between euploid and types of mosaic blastocysts. RESULT(S): Complex mosaic embryos had a significantly lower OIR (10%) than aneuploidy mosaic (50%), double aneuploidy mosaic (45%), and segmental mosaic (41%). There was a tendency for mosaics with 40%-80% abnormal cells to have a lower OIR than those with 40% abnormal cells and those with multiple mosaic abnormalities (chaotic mosaics) are likely to have lower OIRs and should be given low transfer priority.
-
2016 PGDIS Guidelines
-
Hypothesis Like cancer cells, blastomeres of early stage embryos
show Increased expression of gene products favoring cell
progression While lacking cell cycle checkpoint genes
Such a constellation favors genetic instability and mitotic errors in cancer and embryos
Embryo aneuploidy was believed to be mostly meiotic; now known to be mostly mitotic
Kort et al, Hum Reprod 2016
Ghevaria et al, RBMOnline 2016
-
Hypothesis
-
Hypothesis cont. Counterintuitively to the PGS hypothesis,
aneuploidy in trophectoderm may play a role in invasiveness of the embryo during implantation
Supported by excellent live birth rates and low miscarriage rates
Supported by tolerance-inducing aneuploidy recently reported in cancer
-
Conclusions PGS biopsy results:
Are biologically nonsensical
Are technically unfeasible
Are unvalidated
Produce large numbers of false-positive diagnoses and, therefore, have resulted in disposal of large numbers of normal embryos
Fail to improve IVF outcomes
Negatively affect IVF outcomes in at least selected patient populations
-
CHR Staff (* Visiting Scientists) David F Albertini, PhD David H Barad, MS, MD Ali Brivanlou, PhD, MD* Sarah Darmon, PhD, MS Dieter Egli, PhD* Norbert Gleicher, MD Vitaly A Kushnir, MD Emanuela Lazzaroni-Tealdi, MS Kenneth Seier, MS* Aya Shohat-Tal, PhD* Andrea Vidali, MD* Andrea Weghofer, PhD, MS, MBA, MD* Ping Zhou, PhD Yan-Guang Wu, PhD* Yao Yu, PhD*
Affiliates Rockefeller University: Ali Brivanlou, PhD, MD Gist Croft, PhD Salk Institute for Biological Studies: Pradeep Reddy, PhD